BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $176 from $174 and keeps a Buy rating on the shares following a Q1 update that the firm says “was relatively straightforward with a modest revenue beat” and no material pipeline updates. The firm thinks consensus projections for lead product Auvelity in MDD “look prudent/beatable” based on strong Q1 script growth, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $162 from $160 at Baird
- Axsome Therapeutics price target raised to $165 from $160 at Wells Fargo
- Axsome Therapeutics: Strong Market Performance and Promising Growth Potential with Key Catalysts Ahead
- Axsome Therapeutics: Strong Growth Potential with Auvelity’s Market Expansion and Strategic Initiatives
- Axsome Therapeutics Reports Strong Q1 2025 Growth